Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
2seventy bio Inc
TSVT | US
4.97
USD-0.02
-0.40%
TSVT | US
About 2seventy bio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
4.97
Open
4.98
High
5.02
Low
4.87
2seventy bio Inc. a cell and gene therapy company focuses on the research development and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge Massachusetts.
View LessTSVT | US
Risk
63.7
Sharpe
0.17
Luna's Score
33/100
Recommendation
Sell
Luna says (TSVT | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
26.4%1 month
63.7%3 months
62.4%6 months
65.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.09
Debt to equity
1.07
Debt to assets
0.49
Ent. to EBITDA
-1.29
Ent. to rev.
6.95
PEG
-
Other Fundamentals
EBITDA
-176.56M
MarketCap
255.94M
MarketCap(USD)
255.94M
Div. yield
-
Op. margin
-227.01
Erngs. growth
-
Rev. growth
-75.10
Ret. on equity
-51.89
Short ratio
15.77
Short perc.
12.50
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.50
Range1M
0.89
Range3M
1.34
Volumes: Market Activity
Rel. volume
0.34
Price X volume
503.25K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.29 | - | Cheaper |
| Ent. to Revenue | 6.95 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.09 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 62.40 | - | Par |
| Debt to Equity | 1.07 | -1.23 | Expensive |
| Debt to Assets | 0.49 | 0.25 | Expensive |
| Market Cap | 255.94M | - | Emerging |
